Angiogenesis research enjoys growth spurt in the 1990s.
Ziegler
J
J
D000970:Antineoplastic Agents / Q000494:pharmacology*; D003510:Cyclohexanes; D015507:Drugs, Investigational / Q000494:pharmacology*; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors; D006801:Humans; D016898:Interferon-alpha / Q000494:pharmacology; D008222:Lymphokines / Q000037:antagonists & inhibitors; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D011135:Polysaccharides, Bacterial / Q000494:pharmacology; D012717:Sesquiterpenes / Q000494:pharmacology; D013792:Thalidomide / Q000494:pharmacology; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D000970:Antineoplastic Agents; D003510:Cyclohexanes; D015507:Drugs, Investigational; D016228:Endothelial Growth Factors; D016898:Interferon-alpha; D008222:Lymphokines; D011135:Polysaccharides, Bacterial; D012717:Sesquiterpenes; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; C032263:streptococcal polysaccharide type III group B; D013792:Thalidomide; D000077609:O-(Chloroacetylcarbamoyl)fumagillol